Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia
Graviton BioScience, a private company, announced FDA IND clearance for GV101 to treat Friedreich's Ataxia and plans a Phase 2 trial with up to 48 patients starting in Q1 2027. The input ticker MGTX is mentioned only in the executive biography as a prior company founded by Graviton's CEO Dr. Samuel Waksal.
Key figures
- Drug Name
- GV101
- Phase Of Trial
- Phase 2
- Participants
- 48
- Enrollment timing
- Q1 2027
- Prior exposure count
- More than 500
- Trial duration weeks
- 12
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.